Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neoplasms 4Glioma 3Multiple Myeloma 2Melanoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 4trametinib 2relatlimab 2larotrectinib 2dabrafenib 2binimetinib 2Vemurafenib 2Ipilimumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sapanisertib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1ipatasertib 1erdafitinib 1entrectinib 1encorafenib 1defactinib 1copanlisib 1cobimetinib 1capivasertib 1atezolizumab 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Melanoma × trametinib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01682083 2026-04-21

COMBI-AD

Novartis

Phase 3 Completed
870 enrolled 15 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡